manilatimes44m
Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
Bagsværd, Denmark, 24 January 2025 - Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with ...
Novo Nordisk A/S: Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly ...
Novo Nordisk reports 22% weight loss in early subcutaneous amycretin trial
Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying ...
Novo Nordisk shares pop 9% on early-stage weight loss drug trial results
Shares of Novo Nordisk jumped Friday after the Danish pharmaceutical giant reported positive early-stage results for its once ...
Novo Nordisk Shares Surge on New Obesity Drug Results
Novo Nordisk shares rose sharply after the Danish pharmaceutical giant said an experimental weight-loss shot showed patients lost 22% of their bodyweight in a clinical trial. Shares were 9.5% higher ...